# Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma

> **NCT03709953** · PHASE2 · UNKNOWN · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 33 (estimated)

## Conditions studied

- Lung Carcinoma

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03709953
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-19
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-04-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2018-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03709953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03709953, "Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03709953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*